高视医疗(02407)公布,公司获受托人告知,自2024年10月4日起至2024年11月18日止,受托人已动用约514万港元于市场上按每股约10.77港元的平均代价购买合共47.72万股股份(占于本公告日期已发行股份总数约0.32%)。据此购买的股份将用作本计划项下合资格参与者的奖励,以激励彼等为集团作出贡献。此外,本次购买股份亦显示公司对其业务展望及前景充满信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.